Predicted to have ubiquitin ligase-substrate adaptor activity. Predicted to be involved in several processes, including extracellular vesicle biogenesis; positive regulation of ubiquitin-protein transferase activity; and protein ubiquitination. Predicted to localize to several cellular components, including endosome; extracellular vesicle; and plasma membrane. Orthologous to human ARRDC4 (arrestin domain containing 4); INTERACTS WITH (+)-schisandrin B; 6-propyl-2-thiouracil; bisphenol A.
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of ARRDC4 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of ARRDC4 mRNA
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ARRDC4 mRNA, [pirinixic acid co-treated with PPARA] results in decreased expression of ARRDC4 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in decreased expression of ARRDC4 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin